$HCWBJun 16, 2026, 11:00 AMAI processed
HCWB Phase 1 readout: 3/3 in 3 µg/kg cohort showed ≥25% SALT improvement; no serious IL‑2 AEs
AI Summary
HCW Biologics (HCWB) announced preliminary Phase 1 data in alopecia areata: in the 3 µg/kg cohort (n=3, mild AA) all participants had ≥25% reduction in SALT score at 4 and/or 9 weeks after a single subcutaneous dose, and no dose‑limiting toxicities or serious IL‑2‑related adverse events were reported. The update signals an early safety/tolerability win and a small single‑dose efficacy signal, but is limited by very small cohort size, mild baseline disease, and ongoing higher‑dose and correlative analyses needed to confirm activity and define a Phase 2 dose (RP2D targeted by year‑end 2026).
Positives
- All three participants in the 3 µg/kg cohort showed ≥25% SALT improvement after a single dose
- No dose‑limiting toxicities or severe IL‑2‑related events (no capillary leak, cytokine release syndrome, or eosinophilia) reported
- Dose escalation continues and company aims to establish a recommended Phase 2 dose by year‑end 2026
Negatives
- Efficacy signal comes from a very small sample (n=3) of patients with mild alopecia — limited statistical confidence
- Results are from single‑dose cohorts; durability, dose‑response and multi‑dose effects unknown while 8 µg/kg cohort is still enrolling
- Correlative immune endpoints and broader safety/efficacy data are pending and may change the interpretation